Relationship between cognitive impairments and psychopathological symptoms in female schizophrenia subsequent to 8 weeks treatment with antipsychotic drugs.

IF 3.4 2区 医学 Q2 PSYCHIATRY
Shuzhan Gao, Qing Xu, Yanlin Han, Jing Jiang, Fan Wu, Ting Peng, Chenxi Ling, Sulin Ni, Rongrong Zhang, Yidan Ming, Xuzhen Liu, Xijia Xu
{"title":"Relationship between cognitive impairments and psychopathological symptoms in female schizophrenia subsequent to 8 weeks treatment with antipsychotic drugs.","authors":"Shuzhan Gao, Qing Xu, Yanlin Han, Jing Jiang, Fan Wu, Ting Peng, Chenxi Ling, Sulin Ni, Rongrong Zhang, Yidan Ming, Xuzhen Liu, Xijia Xu","doi":"10.1186/s12888-025-06605-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Changes in cognitive impairments and their relationship with psychopathological symptoms during treatment in schizophrenia remain debatable. Especially, there is few studies specifically focusing on female patients. Further exploration of the characteristics of female schizophrenia patients can offer valuable sex-related considerations for clinicians in diagnosis and interventions.</p><p><strong>Methods: </strong>Our study involved 94 female patients with drug-naïve or drug-withdrawal schizophrenia who received antipsychotic drug for 8 weeks, along with 71 age-matched female healthy controls. The MATRICS Consensus Cognition Battery was used to assess cognition in the healthy controls at baseline and in the schizophrenia patients before and after 8 weeks of treatment. The Positive and Negative Syndrome Scale (PANSS) was employed to evaluate the psychopathological symptoms of the patients before and after 8 weeks of treatment.</p><p><strong>Results: </strong>After antipsychotic treatment, 90.43% of the patients showed a reduction rate of more than 25% in their PANSS scores. Psychopathological symptoms and overall cognitive functioning improved significantly (p < 0.05), with the exception of verbal learning and social cognition (p > 0.05). Most cognitive dimensions were negatively correlated with positive symptoms, negative symptoms, and general psychopathological symptoms (p < 0.05, Bonferroni correction), while verbal learning and social cognition were only correlated with negative symptoms (p < 0.05, Bonferroni correction). Multivariate linear regression analysis revealed that improvements in positive symptoms and negative symptoms can predict the improvement in visual learning (p < 0.05) and overall cognitive composite scores (p < 0.05), improved positive symptoms can predict the improvement in the speed of processing (p < 0.05), reasoning and problem-solving(p < 0.05), and improvement in negative symptoms can predict the improvement in attention/vigilance (p < 0.05).</p><p><strong>Conclusions: </strong>Verbal learning and social cognition may serve as core independent cognitive impairments in female schizophrenia. Improvements in the overall cognitive function, along with most cognitive dimensions, appeared to be secondary to the improvement in positive and negative symptoms during the acute stages of antipsychotic treatment.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT03451734.</p>","PeriodicalId":9029,"journal":{"name":"BMC Psychiatry","volume":"25 1","pages":"211"},"PeriodicalIF":3.4000,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11889899/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12888-025-06605-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Changes in cognitive impairments and their relationship with psychopathological symptoms during treatment in schizophrenia remain debatable. Especially, there is few studies specifically focusing on female patients. Further exploration of the characteristics of female schizophrenia patients can offer valuable sex-related considerations for clinicians in diagnosis and interventions.

Methods: Our study involved 94 female patients with drug-naïve or drug-withdrawal schizophrenia who received antipsychotic drug for 8 weeks, along with 71 age-matched female healthy controls. The MATRICS Consensus Cognition Battery was used to assess cognition in the healthy controls at baseline and in the schizophrenia patients before and after 8 weeks of treatment. The Positive and Negative Syndrome Scale (PANSS) was employed to evaluate the psychopathological symptoms of the patients before and after 8 weeks of treatment.

Results: After antipsychotic treatment, 90.43% of the patients showed a reduction rate of more than 25% in their PANSS scores. Psychopathological symptoms and overall cognitive functioning improved significantly (p < 0.05), with the exception of verbal learning and social cognition (p > 0.05). Most cognitive dimensions were negatively correlated with positive symptoms, negative symptoms, and general psychopathological symptoms (p < 0.05, Bonferroni correction), while verbal learning and social cognition were only correlated with negative symptoms (p < 0.05, Bonferroni correction). Multivariate linear regression analysis revealed that improvements in positive symptoms and negative symptoms can predict the improvement in visual learning (p < 0.05) and overall cognitive composite scores (p < 0.05), improved positive symptoms can predict the improvement in the speed of processing (p < 0.05), reasoning and problem-solving(p < 0.05), and improvement in negative symptoms can predict the improvement in attention/vigilance (p < 0.05).

Conclusions: Verbal learning and social cognition may serve as core independent cognitive impairments in female schizophrenia. Improvements in the overall cognitive function, along with most cognitive dimensions, appeared to be secondary to the improvement in positive and negative symptoms during the acute stages of antipsychotic treatment.

Trial registration: ClinicalTrials.gov Identifier: NCT03451734.

求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Psychiatry
BMC Psychiatry 医学-精神病学
CiteScore
5.90
自引率
4.50%
发文量
716
审稿时长
3-6 weeks
期刊介绍: BMC Psychiatry is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of psychiatric disorders, as well as related molecular genetics, pathophysiology, and epidemiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信